Fig. 3From: Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation studyAssumptions and indirect comparisons to obtain estimations for the progression free survival of comparatorsBack to article page